Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

被引：19
|
作者：
Sud, Rohit [1 ]
Friedberg, Jonathan W. [1 ]
机构：
[1] Univ Rochester, Dept Med, James P Wilmot Canc Ctr, Rochester, NY 14627 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷 / 12期
关键词：
D O I：
10.3324/haematol.2008.000984
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1776 / 1780
页数：5
相关论文
共 50 条
  • [31] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Vacirca, Jeffrey
    Tabbara, Imad
    Acs, Peter
    Shumaker, Grace
    [J]. BLOOD, 2010, 116 (21) : 1157 - 1157
  • [32] Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
    Ivanov, Vadim
    Coso, Diane
    Chetaille, Bruno
    Esterni, Benjamin
    Olive, Daniel
    Aurran-Schleinitz, Therese
    Schiano, Jean Marc
    Stoppa, Anne-Marie
    Broussais-Guillaumot, Florence
    Blaise, Didier
    Bouabdallah, Reda
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2508 - 2513
  • [33] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    [J]. SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [34] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [35] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [36] Rituximab maintenance therapy in diffuse large B-cell lymphoma
    Trajkova, S.
    Panovska-Stavridis, I.
    Stojanovik, A.
    Dukovski, D.
    Cevreska, L.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S23
  • [37] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [38] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [39] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [40] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    [J]. ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
12345